Ann: Production & market release of new, next generation sensors, page-4

Launching another sensor is great news and delivery by the CTO on the 2021 pipeline commitment is laudable.
However, another "significant" announcement that is NOT price sensitive.
We need to see a track record of converting technical sucess into commercial success.
ADR now have proliferation of SKUs that must be costing in the region of $1m each to develope and no evidence of commercial success. There is a real danger of operational cost escalation as they put more " cars in the showroom" that need supply chain and infrasturture to support them with no evidence of revenue coming in.
ADR is at risk of being the next and certainly not the last product company with a great product designed to serve a large opportunity that fails.

I do like the pipeline delivery
I dont like SKU proliferation ahead of revenue
I dont like, based on recent reports, their continued reliance on AZ/clinical trials. Something they told us they would stop over 3 years ago
I dont like them being a single product/tech company, the platform guys own the patient/doctor relationship NOT the widget guys - race to the bottom on price
I did like their 2021/2 respiratory ecosystem/platform strategy. CEO never delivered that/killed it ?, no word on the platform (apart from integrating with someone elses and therebye handing control of the patient/doctor relationship to someone else), not a single third party device of the many they identifed announced as to be integrated to their platform - see below from 18/03/21 raise pitch deck chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.adherium.com/media/1669/adherium-investor-presentation-march-2021.pdf
I dont understand what Trudell are doing - not a single announcement on any revenue from them
I do think ADR can succeed
I do believe the current team has given it a good shot, are they the right Leader or Board needed to succeed ?